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Abstract Breast cancer guidelines advise sentinel lymph
node biopsy (SLNB) in patients with ductal carcinoma
in situ (DCIS) on core biopsy at high risk of invasive
cancer or in case of mastectomy. This study investigates
the incidence of SLNB and SLN metastases and the rele-
vance of indications in guidelines and literature to perform
SLNB in order to validate whether SLNB is justified in
patients with DCIS on core biopsy in current era. Clinically
node negative patients diagnosed from 2004 to 2013 with
only DCIS on core needle biopsy were selected from a
national database. Incidence of SLN biopsy and metastases
was calculated. With Fisher exact tests correlation between
SLNB indications and actual presence of SLN metastases
was studied. Further, underestimation rate for invasive
cancer and correlation with SLN metastases was analysed.
910 patients were included. SLNB was performed in 471
patients (51.8 %): 94.5 % had pN0, 3.0 % pN1mi and
2.5 % pN1. Patients undergoing mastectomy had 7 % SLN
metastases versus 3.5 % for breast conserving surgery
(BCS) (p = 0.107). The only factors correlating to SLN
metastases were smaller core needle size (p = 0.01) and
invasive cancer (p\ 0.001). Invasive cancer was detected
in 16.7 % by histopathology with 15.6 % SLN metastases
versus only 2 % in pure DCIS. SLNB showed metastases in
5.5 % of patients; 3.5 % in case of BCS (any
histopathology) and 2 % when pure DCIS was found at
definitive histopathology (BCS and mastectomy). Conse-
quently, SLNB should no longer be performed in patients
diagnosed with DCIS on core biopsy undergoing BCS. If
definitive histopathology shows invasive cancer, SLNB can
still be considered after initial surgery.
Keywords DCIS  Sentinel lymph node biopsy 
Incidence  Treatment
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Introduction
Since 1989, population-based breast cancer screening was
gradually implemented in the Netherlands, aiming at
reduced breast cancer mortality by early breast cancer
detection. This has also led to an increased detection rate of
(asymptomatic) calcifications on mammography, in par-
ticular since the introduction of digital mammography.
Calcifications can be a sign of ductal carcinoma in situ
(DCIS). DCIS is considered a non-obligate precursor lesion
of breast cancer [1, 2]. DCIS represents 15–25 % of all
(pre-) malignant lesions detected by screening [1].
Treatment of DCIS consists of breast conserving surgery
(BCS), frequently followed by radiotherapy, or mastec-
tomy, depending on size of the area with DCIS and breast,
grade and preference of the patient. Indications for a sen-
tinel lymph node biopsy (SLNB) are based on the risk for
invasive breast cancer. According to literature, invasive
breast cancer is found in up to 30 % of excision specimens
after diagnosis of pure DCIS on core biopsy. [3–21] The
indications vary among Dutch, English and American
breast cancer guidelines and include a solid mass on
imaging, extensive calcifications, lesion larger than 25 mm
on imaging, a palpable mass, high-grade DCIS, or age
below 55 years [22–24].
For the treatment of invasive breast cancer, there is a
trend towards minimizing invasive staging and treatment of
the axilla in clinically node negative patients with limited
sentinel lymph node (SLN) metastases [25, 26]. Several
independent randomized clinical trials are even investi-
gating whether SLNB can be safely omitted in clinically
node negative invasive breast cancer patients treated with
breast conserving therapy (BCT) [27, 28]. If de-escalation
of invasive axillary treatment is already considered to be
safe for minimal SLN metastases in case of invasive breast
cancer, this might be even truer for axillary management in
case of DCIS. Here we investigate the incidence of SLNB,
SLN metastases and relevance of indications in guidelines
and literature to perform SLNB in order to validate whether
SLNB is justified in patients with DCIS on core biopsy in
current era
Methods
Study design and patients
The acquisition of informed consent for this retrospective
study was waived by the medical ethics committee of
Maastricht University Medical Centre, Canisius-Wil-
helmina Hospital, Catharina Hospital and the Netherlands
Cancer Institute. All consecutive patients preoperatively
diagnosed with and treated for DCIS in one centre from
2004 to 2013, and from 2008 to 2013 in the other centres,
were selected from the national pathological PALGA
database (‘Nationwide network and registry of histo- and
cytopathology in the Netherlands’) and considered for
inclusion [29]. Clinically node negative patients were
included. Patients with ipsilateral invasive breast cancer
were excluded. The following data were extracted from the
medical records of all patients: radiology outcomes, core
needle biopsy methods, surgical procedures and pathology
reporting on tumour type, grade, size, and (sentinel) lymph
nodes.
Radiological and surgical techniques
Core needle biopsy was generally performed stereotactic in
case of calcifications and ultrasound- or MR-guided in case
of a mass lesion without calcifications. To confirm the
presence of calcifications, a radiograph of the biopsies was
performed [30]. Surgical treatment of DCIS consisted of
BCS or mastectomy, depending on size of the area with
DCIS and breast, grade and preference of the patient. The
SLN was identified using the triple technique, consisting of
lymphoscintigraphy, blue dye, and a gamma probe. Lymph
nodes that were radioactive, blue-stained, or suspicious for
malignancy at palpation were removed.
Pathological techniques
Core biopsies and SLN’s were routinely processed and
stained with haematoxylin and eosin. SLNs were sliced with
amaximum thickness of 5 mm. Each paraffin block was step
sectioned at 250–500-lm intervals at three levels and stained
with haematoxylin and eosin. If no metastasis was detected
with haematoxylin and eosin, immunohistochemical stain-
ing was performed with anti-cytokeratin antibody MNF116
or AE1CK18. Each lymph node was categorized as benign
(pN0), isolated tumour cells (pN0(i?)) (\0.2 mm),
micrometastasis (pN1mi) (0.2–2.0 mm) or macrometastasis
(pN1-3) ([2.0 mm) [23].
The surgical breast specimen was inked according to a
generally agreed colour coding system, sliced with a
maximal thickness of 5 mm and routinely processed. DCIS
and, if present, invasive breast cancer was classified into
grade I, II or III according to the modified Bloom-
Richardson grading system.
Statistical analyses
Statistical analyses were performed using Statistical
Package for the Social Sciences (SPSS), version 22.0 (IBM
Corporation, Armonk, NY, USA). The incidence of the
performance of SLNB and if performed SLN metastases in
DCIS patients was calculated. Furthermore, a correlation
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between the indications in the guidelines and literature
(mastectomy, solid mass on imaging, extensive microcal-
cifications, lesion[25 mm on imaging, palpable mass,
high-grade DCIS, age\55, core needle biopsy method,
core needle biopsy size) for performing an SLNB with the
actual presence of SLN metastases was analysed. Also, the
incidence of invasive breast cancer in definitive
histopathology and the correlation between an invasive
component and SLN metastases was evaluated. All corre-
lations were analysed with the Fisher exact test. Subse-
quent logistic regression analysis was not performed due to
the small amount of significant correlations. To examine
the consequences of omission of SLNB on systemic ther-
apy indication, the number of patients receiving systemic
therapy was studied as was the number of times SLN
metastases were the sole indicator to start systemic therapy.
A p value of\0.05 was considered statistically significant.
Descriptive categorical data are presented as proportions
and absolute numbers. Continuous variables are presented
as means with standard deviations (SD).
Results
A total of 1251 patients were considered for inclusion.
Subsequently, 341 patients were excluded for the following
reasons: 171 had suspicion for an ipsilateral invasive car-
cinoma, 167 were incorrectly coded and 3 objected to use
their medical record for research purposes. Finally, 910
patients were included. Table 1 summarizes all patient and
diagnostic characteristics.
Table 1 Patient demographics and tumour characteristics of all 910 patients and divided per centre
MUMC N = 154 CWZ N = 171 NKI N = 428 CZE N = 157 Total N = 910
Median age in years (range) 60 (33–84) 58 (32–81) 55 (27–90) 58 (30–80) 57 (27–90)
DCIS biopsy (%)
Grade 1 31 (20.1) 26 (15.2) 110 (25.7) 33 (21.0) 200 (22.0)
Grade 2 67 (43.5) 45 (26.3) 189 (44.2) 47 (29.9) 348 (38.2)
Grade 3 56 (36.4) 100 (58.5) 129 (30.1) 77 (49.1) 362 (39.8)
Palpable mass (%) 27 (17.5) 12 (7.0) 40 (9.3) 1 (0.6) 80 (8.8)
Mammography (%)
No abnormalities 7 (4.5) 5 (2.9) 9 (2.1) 1 (0.6) 22 (2.4)
Calcifications 117 (76.0) 160 (93.6) 360 (84.1) 146 (93.0) 783 (86.0)
Mass 13 (8.5) – 10 (2.3) 3 (1.9) 26 (2.9)
Calcification and mass 17 (11.0) 6 (3.5) 49 (11.5) 7 (4.5) 79 (8.7)
Ultrasound (%)
In total performed 154 (100) 154 (90.1) 295 (68.9) 157 (100) 761 (83.6)
No abnormalities 101 (65.6) 118 (76.6) 128 (43.4) 134 (85.4) 481 (63.3)
Benign lesion 1 (0.6) 3 (2.0) 4 (1.4) 1 (0.6) 9 (1.2)
Suspect lesion 32 (20.8) 16 (10.4) 124 (42.0) 19 (12.1) 191 (25.1)
Other 20 (13.0) 17 (11.0) 39 (13.2) 3 (1.9) 79 (10.4)
MRI (%)
In total performed 105 (68.2) 10 (5.8) 285 (66.6) 9 (5.7) 409 (44.9)
No abnormalities 17 (16.2) – 103 (36.1) 3 (33.3) 123 (30.0)
Non mass like enhanced 64 (61.0) 7 (70.0) 157 (55.1) 5 (55.6) 233 (57.0)
Massa enhanced 19 (18.0) 1 (10.0) 21 (7.4) 1 (11.1) 42 (10.3)
Asymmetry 5 (4.8) 2 (20.0) 4 (1.4) – 11 (2.7)
Operation (%)
Lumpectomy 66 (42.9) 100 (58.5) 223 (52.1) 126 (80.3) 515 (56.6)
Mastectomy 88 (57.1) 71 (41.5) 205 (47.9) 31 (19.7) 395 (43.4)
MUMC Maastricht University Medical Centre, Maastricht, CWZ Canisius-Wilhelmina Hospital, Nijmegen, NKI Netherlands Cancer Institute,
Amsterdam, CZE Catharina Hospital, Eindhoven, DCIS Ductal carcinoma in situ, MRI Magnetic Resonance Imaging
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An SLNB was performed in 471 patients (51.8 %)
(Fig. 1). The SLN showed no metastases in 427 patients
(90.7 %), isolated tumour cells in 18 (3.8 %),
micrometastases in 14 (3.0 %), and macrometastases in 12
(2.5 %) (Table 2). Of the 26 patients with SLN (mi-
cro)metastases (Table 3), 14 patients (53.8 %) underwent
completion axillary lymph node dissection (cALND). In 9
out of 14 patients (64.3 %), no additional lymph node
metastases were found, in one an additional micrometas-
tasis and in four macrometastases. Final histopathology, of
all axillary surgery, showed pN0 in 427 (90.7 %),
pN0i? in 18 (3.8 %), pN1mi in 12 (2.5 %), and CpN1 in
14 patients (3.0 %).
All guidelines include a mastectomy as an indication to
perform an SLNB. A mastectomy was performed in 395
patients (43.4 %) and BCS in 515 (56.6 %). Of the patients
treated with mastectomy, 68.6 % underwent an SLNB.
SLN metastases were found in 7 % of patients; of which
3.7 % micrometastases and 3.3 % macrometastases. After
cALND, final results were 3.0 % pN1mi and 4.0 % CpN1.
Of the patients treated with BCS, 38.8 % underwent
SLNB. In 3.5 % a metastasis was detected in the SLN, of
which 2 % micrometastases and 1.5 % macrometastases.
Final histopathology results did not change pN-status fol-
lowing cALND in BCS patients. The difference in SLN
results between patients undergoing mastectomy and
patients undergoing BCS was not statistically significant
(p = 0.107) (Table 3).
Other indications to perform an SLNB known before
surgery like a palpable tumour, mass on mammography,
tumour larger than 25 mm, high-grade DCIS, age below 55
and core biopsy method (stereotactic versus sonographi-
cally) were not significantly correlated to SLN metastases
(Tables 4). The only variable correlated to SLN metastases
was smaller core needle size (p = 0.010). Core needle size
was known in 336 patients. Upstaging to invasive breast
cancer occurred in 28 out of 207 (13.5 %) patients diag-
nosed with a large 9–11G needle and 26 out of 129
(20.2 %) diagnosed with a smaller 14–19G needle. This

































Fig. 1 Results of the sentinel lymph node biopsy. DCIS Ductal carcinoma in situ. SLNB sentinel lymph node biopsy. pN0 No metastases.
pN0i ? Isolated tumour cells. pN1mi micrometastasis. pN1 1–3 macrometastases
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indication ‘extensive microcalcifications on preoperative
imaging’ was not studied, since the extent of calcifications
was unknown for the patients in our cohort (only yes/no).
In 152 patients (16.7 %), the initial DCIS on core biopsy
was upstaged to invasive cancer in definitive histopathol-
ogy (Table 2). An SLNB was performed in 80.3 % of these
patients and showed metastases in 15.6 % of which 4.9 %
pN1mi and 10.7 % pN1 (Table 5). In 349 out of 758
patients (46.0 %) with pure DCIS in definitive
histopathology an SLNB was performed and showed
metastases in 2 % of which 1.7 % pN1mi and 0.3 %
pN1 (Table 5). Invasive breast cancer was positively cor-
related to SLN metastases (p\ 0.001) (Table 4). Numbers
are too low to perform further analysis on these findings.
Systemic therapy was indicated for 105 patients
(11.5 %), according to current Dutch guidelines, because
of tumour characteristics. In 17 of these patients (1.9 %)
this indication was solely based on the presence of SLN
metastases.
Discussion
The aim of this study was to investigate the incidence of
SLN metastases in patients with pure DCIS on core biopsy
and explore whether this justifies current recommended
indications for performing SLNB as published in current
guidelines and literature. In our cohort, SLNB was per-
formed in 51.8 % of patients and showed 5.5 % SLN
metastases, of which 3.0 % pN1mi and 2.5 % pN1. Final
histopathology after breast surgery, SLNB and cALNDs,
showed 2.5 % pN1mi and 3.0 % pN1, and invasive breast
cancer in 16.7 %.
Our results are consistent with the recent studies of
Francis and Prendeville [17, 19]. Francis showed 2.9 %
pN1mi and 2.4 % pN1 and 21 % invasive breast cancer
[17], Prendeville found 0.5 % pN1, no micrometastases
and 30 % invasive breast cancer [19]. The differences with
this study are that Francis only included patients that
underwent SLNB and that Prendeville had a study popu-
lation of only 296 patients.
The English, Dutch, and American breast cancer
guidelines all advice an SLNB in patients undergoing a
mastectomy, since it cannot be performed afterwards [22–
24] Further, mastectomy is often performed in case of a
large diameter of a lesion or calcifications on mammog-
raphy, which is suggested to correlate with an elevated
risk of invasive carcinoma [1]. In our cohort, an SLNB
was performed in only 68.6 % of patients undergoing a
mastectomy, and in 38.8 % in case of BCS. A positive
SLN was detected in 7.0 versus 3.5 %, respectively,
though there was no significant correlation between type
Table 2 Pathology results of SLNB and excision specimen of the 910 patients
MUMC N = 154 CWZ N = 171 NKI N = 428 CZE N = 157 Total N = 910
SLNB
In total performed (%) 105 (68.2) 76 (44.4) 177 (41.4) 113 (72.0) 471 (51.8)
No metastases 92 (87.6) 70 (92.2) 159 (89.8) 106 (93.8) 427 (90.7)
Isolated tumour cells 11 (10.5) 3 (3.9) 3 (1.7) 1 (0.9) 18 (3.8)
Micrometastases 2 (1.9) 3 (3.9) 8 (4.5) 1 (0.9) 14 (3.0)
Macrometastases – _ 7 (4.0) 5 (4.4) 12 (2.5)
Final pathology
DCIS excision (%)
No residual 6 (3.9) 12 (7.0) 37 (8.6) 13 (8.3) 68 (7.5)
DCIS grade 1 17 (11.0) 15 (8.8) 94 (22.0) 24 (15.3) 150 (16.5)
DCIS grade 2 55 (35.7) 44 (25.7) 164 (38.3) 34 (21.6) 297 (32.6)
DCIS grade 3 76 (49.4) 100 (58.5) 133 (31.1) 86 (54.8) 395 (43.4)
Invasive cancer (%) 27 (17.5) 24 (14.0) 75 (17.5) 26 (16.6) 152 (16.7)
IDC grade 1 9 (33.3) 7 (29.2) 26 (34.7) 7 (26.9) 49 (32.2)
IDC grade 2 10 (37.1) 11 (45.8) 27 (36.0) 12 (46.2) 59 (38.8)
IDC grade 3 4 (14.8) 4 (16.7) 12 (16.0) 2 (7.7) 22 (14.5)
Other 4 (14.8) 2 (8.3) 10 (13.3) 5 (19.2) 22 (14.5)
MUMC Maastricht University Medical Centre, Maastricht, CWZ Canisius-Wilhelmina Hospital, Nijmegen, NKI Netherlands Cancer Institute,
Amsterdam, CZE Catharina Hospital, Eindhoven, SLNB Sentinel lymph node biopsy, DCIS Ductal carcinoma in situ, IDC Invasive ductal
carcinoma
Breast Cancer Res Treat (2016) 156:517–525 521
123






















1 53 Yes No 10 2 pN1mi Mast. 2  Yes 6 pN1mi
2 51 No No 10 2 pN1 Mast. 3  Yes 9 pN1
3 56 No No 76 1 pN1 Mast. 1 70 Yes 6 pN1
4 64 No Yes 40 3 pN1 Mast. 3 40 No pN2
5 60 No Yes 10 2 pN1 Lump. 1  Yes 10 pN1
6 46 Yes Yes 50 2 pN1 Mast. 3  Yes 15 pN1
7 34 Yes No 70 3 pN1mi Mast. 3 90 Yes 5 pN1mi
8 43 Yes No 52 3 pN1 Mast. 3 35 Yes 13 pN1
9 56 No No 41 3 pN1mi Lump. 3 40 Yes 9 pN1mi
10 53 No No 25 2 pN1mi Lump. 2 25 No pN1mi
11 49 No No 56 2 pN1mi Mast. 2 50 Yes 11 pN1
12 35 No No 120 3 pN1mi Mast. 2 100 No pN1mi
13 39 No No 80 2 pN1 Mast. 2 90 Yes 7 pN1
14 51 No No 20 2 pN1mi Mast. 3 6 Yes 26 pN1mi
15 69 No Yes 15 1 pN1mi Lump. 1 30 Yes 9 pN1mi
16 51 No No  2 pN1mi Mast. 3 60 No pN1mi
17 53 No No  3 pN1mi Mast. 3  No pN1mi
18 57 No No  3 pN1mi Mast. 3  No pN1mi
19 58 Yes Yes 20 2 pN1mi Lump. 2 39 Yes 4 pN1mi
20 54 No No 80 2 pN1mi Mast. 3 105 Yes 90 pN3a
21 60 No No 21 3 pN1 Mast. 3  Yes 4 pN1
22 68 No No 60 3 pN1 Mast. 3 8 Yes 7 pN1
23 59 No No  3 pN1 Lump. 3 20 Yes 14 pN1
24 59 No No 20 2 pN1 Lump. 3 20 Yes 4 pN1
25 71 No No 31 2 pN1 Mast. 3 100 Yes 25 pN1
26 67 No No 12 3 pN1mi Mast. 3 55 No – pN1mi
Yrs years, US ultrasound, DCIS Ductal carcinoma in situ, SLNB sentinel lymph node biopsy, Mast. Mastectomy, Lump. Lumpectomy, cALND
completion axillary lymph node dissection
* If performed
Table 4 Independent
predictors of SLN metastases of
the 471 patients undergoing an
SLNB
Odds ratio 95 % Confidence interval p value
Lower Upper
Age (B55 vs.[55 years) 0.846 0.384 1.867 0.691
Palpable tumour 1.881 0.679 5.210 0.211
Size tumour (B25 vs.[25 mm) 1.193 0.495 2.878 0.435
Mass on mammography 1.558 0.566 4.290 0.377
High-grade DCIS 0.686 0.308 1.526 0.421
Biopsy method (stereotactic vs. sonographic) 1.909 0.682 5.343 0.207
Size core needle (14–18 vs. 9–11 gauge) 7.244 1.444 36.353 0.010
Surgery (lumpectomy vs. mastectomy) 2.079 0.857 5.045 0.107
Invasive ductal carcinoma 9.012 3.686 22.038 \0.001
SLN sentinel lymph node, SLNB sentinel lymph node biopsy, DCIS ductal carcinoma in situ
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of breast surgery and the presence of SLN metastases
(p = 0.107), nor between lesion size[25 mm and SLN
metastases (p = 0.435).
Other indications to perform an SLNB according to the
guidelines and literature where: a solid mass on imaging,
extensive calcifications, lesion larger than 25 mm on
imaging, smaller core needle size, a palpable mass, high-
grade DCIS, or age below 55 years [18, 20, 22, 23].
These indications are based on the risk for invasive breast
cancer. In our study, only a smaller core needle size
(p = 0.010) and invasive carcinoma as final diagnosis
(p\ 0.001) were positively correlated to SLN metastases.
The correlation between smaller core needle size and
SLN metastases might be attributed to a higher rate of
upstaging to invasive breast cancer in patients were a
needle with a smaller core was used. When a large core
needle (9–11G) was used, only 13.5 % was upstaged,
compared to 20.2 % for small core needle. Though this
difference was not statistically significant (p = 0.074),
these numbers show us that the upstaging rate is lower
with a modern, large core needle.
The correlation between invasive carcinoma at final
histopathology and SLN metastases was to be expected.
Also, in 2 % of the patients with pure DCIS at final
histopathology, SLN metastases were found. To our opin-
ion, these cases probably had occult invasion.
In invasive breast cancer, there is a trend to minimize
invasive management of the axilla. Patients with invasive
breast cancer in the ACOSOG Z0011 (pN1) and IBCSG
23-01 (pN1mi) trials, randomized for watchful waiting
after a positive SLN, were likely to have residual lymph
nodal disease in 11–27 %. [25, 26] Even though these
lymph nodes were not surgically removed, overall survival
was not affected and regional recurrence rate low. This
implies that the remaining 5.5 % SLN metastases in our
cohort will not affect overall survival and regional recur-
rence rate. The main difference with ACOSOG Z0011 is
that those patients were mostly treated with adjuvant sys-
temic therapy (97 %) and always underwent BCS with
radiotherapy. Other arguments for safely omitting SLNB in
patients with DCIS on core biopsy could be selected from
the NSABP B-04 trial. [31] Only half of remaining nodal
metastases became clinically relevant. Further, a delayed
ALND, in case lymph nodes became clinically positive
during follow-up, did not affect overall survival and dis-
ease-free survival, in patients with invasive breast cancer
whom were not treated with adjuvant systemic or radiation
therapy [31]. Multiple trials are now investigating the
safety of omitting SLNB in clinically node negative inva-
sive breast cancer patients treated with BCT [27, 28]. DCIS
so far escaped from this trend to minimize invasive staging
and treatment of the axilla.
Biology, loco-regional and systemic therapy all have a
role in survival and (regional) recurrence. In our cohort,
radiotherapy was administrated in case of BCS and rarely
in case of mastectomy. Systemic therapy was indicated in
11.5 % of patients based on the presence of primary
invasive breast cancer characteristics and/or nodal metas-
tases. If no SLNB would have been performed at all in this
population, the indication for systemic therapy would have
been missed in 1.9 % of patients.
Our study is limited by its retrospective design. In
48.2 % an SLNB was not performed. Unfortunately, the
exact reason for (not) performing an SLNB could not be
retrieved. Further, the low event rate of SLN metastases
limits the opportunity to perform comprehensive (prog-
nostic) analyses. This low event rate also implicates that
SLNB is of limited value in patients with DCIS in current
era [32]. The study of Broekhuizen et al. already demon-
strated that the survival of DCIS patients is not affected by
SLN micrometastases [33].
In conclusion, the SLNB contained a metastasis in
5.5 %, of which 2.5 % macrometastases. In patients
undergoing a mastectomy, 7.0 % had SLN metastases. For
BCS this was 3.5 %. None of the guidelines indications to
perform an SLNB was correlated to SLN metastases. The
presence of an invasive component in the excision speci-
men however is significantly correlated to SLN metastases,
with a chance of 15.6 % of SLN metastases in case of
invasive cancer versus only 2 % in case of pure DCIS at
final histopathology.
To our opinion, SLNB should no longer be performed in
patients diagnosed with DCIS on core biopsy in case they
are treated with BCS. SLNB can still be performed after-
wards, if final histopathology reveals invasive breast can-
cer. This way, DCIS patients are not needlessly put at risk
for complications and unnecessary medical costs.
Table 5 Axillary status of
patients that underwent axillary
surgery (SLNB ± cALND)
No metastases Micrometastases Macrometastases Total
DCIS (%) 342 (97.9) 6 (1.7) 1 (0.3) 349
Invasive carcinoma (%) 103 (84.4) 6 (4.9) 13 (10.7) 122
Total (%) 445 (94.5) 12 (2.5) 14 (3.0) 471
SLNB sentinel lymph node biopsy, cALND completion axillary lymph node dissection, DCIS Ductal car-
cinoma in situ
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